featured
Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study
Lancet Oncol 2020 May 13;[EPub Ahead of Print], GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, JM Cleary, DV Catenacci, MJ Borad, J Bridgewater, WP Harris, AG Murphy, DY Oh, J Whisenant, MA Lowery, L Goyal, RT Shroff, AB El-Khoueiry, B Fan, B Wu, CX Chamberlain, L Jiang, C Gliser, SS Pandya, JW Valle, AX ZhuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.